Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 171

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 5
Chunk 171
---
 the periods indicated.
 

  Operating Segment:           2024                   2023                   2022     
--------------------------------------------------------------------------------------
                                                          (U.S. dollars, in thousands)
Agriculture                       $5,889                  $3,791                  $876
Industrial application             2,219                   1,075                    72
Human health                          80                     487                   513
Unallocated                          323                     287                   214
Total                             $8,511                  $5,640                $1,675
Geographical Breakdown of Net Revenues
 
The following table presents net revenues by geographic breakdown of customers as a percentage of our total net revenues for the periods indicated. This data refers to the location of the customer and does not take into consideration the location of the end-user (to the extent it is different).

Geographical Region:      2024            2023            2022      
--------------------------------------------------------------------
United States                 46   %          65   %          51   %
Israel                         7   %          16   %          45   %
Other                         47   %          19   %           4   %
Total                        100   %         100   %         100   %
Cost of Revenues
 
Cost of revenues primarily consists of development costs incurred in conjunction with our collaborations, which include: salaries and related personnel costs for our research and development employees working on the collaborations; payments to third party suppliers and producers; and the cost of disposable materials (such as seeds, laboratory supplies, fertilizer, water and soil), and expenses related to retaining advisors, who primarily consist of biological advisors.
Operating Expenses
 
Research and Development Expenses, net: Research and development expenses primarily consist of costs related to our internal or independent research and development activities, as opposed to development costs incurred in connection with our collaborations (which are included in cost of revenues). These independent activities of ours include the further development of our product pipeline, enhancement and expansion of our CPB platform and improvement of our computational, scientific and validation technologies, know-how and capabilities used by our subsidiaries and product divisions. Research and development costs include: salaries and related personnel costs (including share-based compensation); payments to third party suppliers and subcontractors, field-trials and pre-clinical studies carried out by third parties; cost of disposable materials; expenses associated with participation in professional conferences; operational overhead costs, which include costs related to leasing and operating our office, laboratory facilities and greenhouses; depreciation of property, plant and equipment;